Physician profile
Dana Meredith Chase
NPI 1396888947
$1,289,161.63
in general payments reported to CMS, 2019-2025
41 companies · $145K in 2025
The $145K reported for 2025 was more than what 99% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287K · 2020: $102K · 2021: $100K · 2022: $182K · 2023: $253K · 2024: $219K · 2025: $145K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $372K · Consulting Fee: $133K · Travel and Lodging: $78K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $19K · Food and Beverage: $13K · Honoraria: $1,425 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $372,056.50 |
| Consulting Fee | $133,474.75 |
| Travel and Lodging | $78,370.44 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $19,356.25 |
| Food and Beverage | $12,732.00 |
| Honoraria | $1,425.00 |
| Education | $121.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $468,733.88 | 2019-2025 | Lynparza, Enhertu, Imfinzi |
| Glaxosmithkline, LLC. | $335,872.43 | 2020-2025 | Jemperli, Zejula |
| Eisai INC. | $81,380.98 | 2019-2025 | |
| Tesaro, INC. | $62,489.27 | 2019 | |
| Genmab U.S., INC. | $60,356.23 | 2021-2024 | Tivdak, Epkinly |
| Seagen INC. | $53,014.75 | 2020-2023 | Tivdak |
| Abbvie INC. | $42,126.87 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $39,916.89 | 2019-2024 | Keytruda |
| Clovis Oncology, INC. | $23,538.46 | 2019-2022 | |
| Genentech USA, INC. | $19,557.10 | 2019 | |
| Pfizer INC. | $16,344.94 | 2019-2025 | |
| Intuitive Surgical, INC. | $12,747.05 | 2019-2025 | |
| Immunogen, INC. | $10,557.59 | 2023 | Elahere |
| Baxter Healthcare | $9,246.62 | 2020-2024 | |
| Daiichi Sankyo INC. | $7,260.41 | 2025 | Enhertu |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Chase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.